Articles

Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with del(17p): Initial Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
ASH 2019 Wrap-up
Conference Correspondent
Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read More
The iR² Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ASH 2019 Wrap-up
Conference Correspondent
Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant.
Read More
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Health Policy, In the News
Web Exclusives
The Centers for Medicare & Medicaid Services (CMS) has broadened access to Medicare telehealth services so that beneficiaries can receive a wider range of services from their physicians without having to travel to a healthcare facility. Clinicians can bill immediately for services starting March 6, 2020.
Read More
Effective Targeted Therapies in CCA: IDH1 and FGFR
Effective Targeted Therapies in CCA: IDH1 and FGFR
By Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc; Vaibhav Sahai, MBBS, MS
Interview with the Innovators, Cholangiocarcinoma
Videos
Dr Angela Lamarca reviews the current clinical trials with FGFR inhibitors, particularly those with patients with FGFR2 fusion and other genetic aberrations. Dr Vaibhav Sahai highlights those FGFR inhibitors that are nonselective and those that are selective for FGFR1-4, and discusses the clinical trial results with the selective inhibitors, including pemigatinib and infigratinib. He remarks that the response rates and progression-free survival in these trials have been remarkable, far better than what is seen with chemotherapy.
Read More
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
By Phoebe Starr
Hematologic Malignancies, Multiple Myeloma, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—The investigational B-cell maturation antigen (BCMA)-­directed chimeric antigen receptor (CAR) T-cell therapy known as JNJ-4528 induced responses in 100% of 29 evaluable patients with heavily pretreated relapsed or refractory multiple myeloma, according to the results of the phase 1b/2 CARTITUDE-1 clinical trial reported at ASH 2019.
Read More
Investigational Oral Form of Azacitidine Improves Survival as Maintenance Therapy in Patients with Acute Myeloid Leukemia
By Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—An investigational oral form of azacitidine (CC-486) as maintenance therapy induced a statistically significant improvement in overall survival (OS) compared with placebo in patients with newly diagnosed acute myeloid leukemia (AML) who achieved a complete response or complete response with incomplete hematologic recovery after treatment with induction chemotherapy.
Read More
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
By Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—Almost 50% of patients with chronic lymphocytic leukemia (CLL) who received treatment with the triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinu­tuzumab (Gazyva) as first-line therapy achieved undetectable minimal residual disease (MRD) in the bone marrow after only 8 monthly cycles of therapy, according to data presented at ASH 2019.
Read More
Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL
By Phoebe Starr
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—Zanubrutinib (Brukinsa), a novel Bruton tyrosine kinase (BTK) inhibitor—which was approved by the FDA in November 2019 for the treatment of mantle-cell lymphoma—achieved high overall response rate (ORR) and durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including those with high-risk cytogenetics, according to findings presented at ASH 2019.
Read More
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome
By Wayne Kuznar
Emerging Therapies
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—A new CD45-targeting antibody radiation-conjugate, iodine-131 (I-131) apamistamab, may be a less toxic alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens before initiation of adoptive cell therapy, according to results presented at ASH 2019.
Read More
Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer
FDA Approvals, News & Updates
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
On December 16, 2019, the FDA approved a new indication for enzalutamide (Xtandi; Astellas Pharma) for the treatment of patients with metastatic castration-sensitive prostate cancer (CSPC). Enzalutamide was previously approved for patients with castration-­resistant prostate cancer.
Read More

Page 79 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.